The smart ring on the fingers of everyone from athletes to celebrities is heading for the stock market. On 3 September 2026, Oura, the Finnish-founded, San Francisco-based maker of the popular health-tracking ring, filed to go public, planning to list on the Nasdaq under the ticker "OURA". Reports suggest it's seeking to raise as much as $3 billion at a valuation of more than $16 billion. It joins a remarkable wave of listings, from the record-breaking SpaceX float to the huge AI labs whose forecasts are already moving markets.
It's a buzzy, headline-grabbing debut, and a perfect opportunity to understand something many investors get wrong: what a hot IPO actually is, and how to think about one sensibly. This guide looks at Oura's business, the IPO, and the honest realities of investing around a high-profile listing. It's educational, not investment advice, and OURA is used here as an example to research, not a recommendation. If you want to research the stock or the wearables theme, you can explore tech stocks from just $1 with zero commission on the Nemo.money app.
Investors around the world are searching:
- "Oura IPO"
- "Oura stock"
- "OURA ticker"
- "how to buy IPO stock"
- "smart ring stocks"
Meet Oura: A Ring That Became a Health Platform
Oura makes a finger-worn smart ring (priced around $350-400) that tracks sleep, heart rate, temperature, stress, activity and more, paired with an app and a paid subscription that turns the readings into personalised health insights.
- 💍 A distinctive product. Unlike wrist wearables, Oura's ring form has carved out a loyal following, and famous fans (including Jennifer Aniston, Prince Harry, Kim Kardashian and Tom Holland) have boosted its profile.
- 📈 Fast growth. Revenue has soared, from roughly $500 million in 2024 to about $1 billion in 2025, and the company reported around $1.4 billion in revenue over the past twelve months, with nine-month revenue up around 74% year on year.
- 👥 A subscription engine. Oura reports around 5 million paying members (double a year earlier), with roughly 85% sticking around after a year, a recurring-revenue model investors tend to like. It has sold about 3.6 million rings in the past year.
- 🧠 An AI-health pitch. Oura is positioning itself as an "always-on health intelligence platform", emphasising its huge biometric dataset and AI-driven preventive-health ambitions, aiming at a market it argues is far bigger than fitness tracking alone.
In short, Oura is a fast-growing, well-liked company with a genuine product and a recurring-revenue model, which is exactly why its IPO is generating so much excitement.
The Numbers: Impressive, but Read Carefully
Oura's filing shows a business growing quickly, but there's a headline figure that needs explaining, a lesson in reading IPO paperwork carefully:
- 💚 It's profitable on an operating basis. Over the nine months in its filing, Oura generated positive adjusted earnings (adjusted EBITDA of around $107 million) and even a small net income at the operating level, with gross margins around 55%.
- 😱 But the headline shows a huge "loss". The same filing reported a net loss of roughly $924 million. That sounds alarming, until you read the detail: it was driven largely by a one-off, non-cash accounting item (a "deemed dividend" to certain preferred shareholders), not by the business burning through cash.
- 🔍 The lesson. IPO filings are full of technical accounting effects. A scary headline number can mask an underlying business that's actually doing well, or vice versa. Always look past the headline to what's really happening operationally.
This is a useful reminder that IPOs require homework, not just enthusiasm about a product you like.
What Is an IPO, and What Everyday Investors Should Know
An IPO (initial public offering) is when a private company sells shares to the public for the first time, listing on a stock exchange. They generate huge excitement, but there are realities every investor should understand:
- 🎟️ You usually can't buy at the "IPO price". The headline IPO price is generally offered to big institutional investors. Ordinary investors typically buy only once the shares start trading, which can be at a very different (often higher) price. (For a practical look at how everyday investors can follow and prepare for a big listing, see our guide on how investors can prepare for a major IPO.)
- 🎢 First-day pops, and drops. Hot IPOs can jump on day one, but they can also be extremely volatile, and many high-profile IPOs have fallen below their listing price in the months afterwards. Even the biggest, most hyped listing in history saw this: as we explored in what SpaceX's record IPO teaches us about the coming wave of AI listings like OpenAI and Anthropic, its shares eased sharply from their post-listing high once the euphoria faded. Early excitement doesn't guarantee lasting gains.
- 🔒 Beware the "lock-up". Early investors and employees are usually barred from selling for a period (often 90-180 days). When that lock-up expires, a wave of selling can pressure the share price.
- 📊 Less history to judge. Newly public companies have a short public track record, less data, and often sky-high expectations baked into the price. That can mean bigger swings in both directions.
None of this means IPOs are bad, but it means they deserve extra caution, not less.
The Honest Risks
Beyond general IPO dynamics, Oura has its own specific risks worth weighing:
- ⚠️ Giant competition is circling. The wearables market is dominated by much larger players. Samsung has launched its own Galaxy Ring, Apple is reportedly developing wearables (potentially including a ring), and Whoop, Google's Fitbit and others compete hard. Even a profitable specialist like Garmin, quietly doing $2bn a quarter, thrives only by owning a defensible niche, a small, single-product-category company faces enormous, well-funded rivals.
- ⚠️ A niche within a niche. Smart rings are still a small slice of the overall wearables market. Oura is a leader in rings, but rings themselves must keep winning converts.
- ⚠️ A legal cloud. Oura has reportedly faced a proposed class-action lawsuit alleging it misled users about the accuracy of its sleep tracking, a reminder that health-tech claims attract scrutiny.
- ⚠️ Valuation and expectations. A $16 billion-plus target values Oura richly for its size. High expectations leave little room for disappointment if growth slows.
- ⚠️ The IPO-hype trap. Buying into a buzzy IPO on excitement, at whatever price the market opens, is one of the most common ways investors get burned. A great product is not the same as a great investment at any price.
The takeaway: Oura is a genuinely impressive company, but a high-profile IPO calls for more research and more caution, not less. Judge the business, the valuation and the risks, not the buzz.
How to Research IPOs and Wearables Stocks with Nemo.money
Whether you're curious about Oura, the wider wearables and health-tech space, or how to approach IPOs, the Nemo.money app is built to help you research before you decide:
- Invest from Just $1: Fractional shares let you start small with eligible stocks and ETFs.
- Zero-Commission Trading: Buy and sell eligible US-market stocks and ETFs without commission fees.
- AI-Powered Insights & Nemes: Explore data, sentiment and curated themed collections (Nemes), including technology and health themes, as a research starting point.
- Earn 6% AER on Idle Cash: Uninvested cash in your wallet earns 6% AER, paid daily in USD, while you research and decide.
Frequently Asked Questions (FAQs)
Is Oura going public?
Yes. On 3 September 2026, Oura (the smart-ring maker) filed with the US Securities and Exchange Commission to go public, planning to list on the Nasdaq under the ticker "OURA". Reports suggest it is seeking to raise as much as $3 billion at a valuation of more than $16 billion. The exact timing, share price and details depend on the SEC review and market conditions, so they are not yet finalised.
What does Oura do?
Oura makes a smart ring (priced around $350-400) that tracks health and wellness metrics, sleep, heart rate, temperature, stress and activity, paired with an app and a paid subscription that turns the data into personalised insights. It positions itself as an "always-on health intelligence platform" using AI. Oura reports around 5 million paying members and about $1.4 billion in annual revenue, and competes in the fast-growing health-wearables market.
Why did Oura's filing show a $924 million loss if it's doing well?
Because the headline loss was driven largely by a one-off, non-cash accounting item, a "deemed dividend" to certain preferred shareholders, rather than the business losing money operationally. On an operating basis, Oura reported positive adjusted earnings and even a small net income over the same period, with healthy gross margins. It's a good example of why you should read past the headline number in IPO filings to understand the underlying business. This is general information, not advice.
Can I buy Oura shares at the IPO price?
Usually not. The official "IPO price" is typically offered to large institutional investors. Everyday investors generally can only buy once the shares begin trading on the exchange, which may be at a higher (or lower) price than the IPO price. IPO shares can also be very volatile in early trading. Apps like Nemo.money let you research and invest in tech stocks and ETFs from just $1 with zero commission once they are trading and available.
Are IPOs a good investment?
IPOs can be exciting but carry particular risks: everyday investors often can't buy at the IPO price, early trading can be very volatile, newly public companies have limited track records, and "lock-up" expiries can pressure prices later. Many high-profile IPOs have fallen below their listing price after the initial buzz. Whether any IPO suits you depends on your own research, goals and risk tolerance. A popular product or brand doesn't guarantee a good investment. This is not advice, and your capital is at risk.
Final Thoughts: A Great Product Is Not a Guaranteed Investment
Oura's journey, from a Finnish start-up to a $16 billion IPO candidate with millions of devoted members and celebrity fans, is genuinely impressive. It has a distinctive product, fast growth, a loyal subscription base and a bold AI-health vision. It's easy to see why the listing is generating so much buzz.
But for investors, the buzz is exactly what to be careful of. A hot IPO is one of the moments when excitement most often overrides good judgment: you usually can't buy at the IPO price, early trading can be wild, expectations are sky-high, and even the strongest brands can disappoint as stocks. The smart approach is to treat Oura's IPO as an invitation to research, not a race to buy: understand the business, read past the headline numbers, weigh the giant competition and the valuation, and remember that loving the product on your finger tells you nothing about whether the shares are a good buy. Do the homework, respect the risks, and never confuse a great gadget with a great investment.
Explore eligible US-listed stocks from $1 with zero commission on the Nemo.money app.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#Oura #IPO #Investing #Wearables #NemoMoney
Terms and conditions apply. This is not investment advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
